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ABSTRACT:
Non-reproducible  sequence  artefacts  are  frequently  detected  in  DNA  from 
formalin-fixed and paraffin-embedded (FFPE) tissues. However, no rational strategy 
has been developed for reduction of sequence artefacts from FFPE DNA as the 
underlying causes of the artefacts are poorly understood. As cytosine deamination 
to uracil is a common form of DNA damage in ancient DNA, we set out to examine 
whether treatment of FFPE DNA with uracil-DNA glycosylase (UDG) would lead to 
the reduction of C>T (and G>A) sequence artefacts. Heteroduplex formation in high 
resolution melting (HRM)-based assays was used for the detection of sequence 
variants in FFPE DNA samples. A set of samples that gave false positive HRM results 
for screening of the E17K mutation in exon 4 of the AKT1 gene were chosen for 
analysis. Sequencing of these samples showed multiple non-reproducible C:G>T:A 
artefacts. Treatment of the FFPE DNA with UDG prior to PCR amplification led to a very 
marked reduction of the sequence artefacts as indicated by both HRM and sequencing 
analysis. Similar results were shown for the BRAFV600 region in the same sample set 
and EGFR exon 19 in another sample set. UDG treatment specifically suppressed the 
formation of artefacts in FFPE DNA as it did not affect the detection of true KRAS 
codon 12 and true EGFR exon 19 and 20 mutations. We conclude that uracil in FFPE 
DNA leads to a significant proportion of sequence artefacts. These can be minimised 
by a simple UDG pre-treatment, which can be readily carried out in the same tube as 
the PCR, immediately prior to commencing thermal cycling. HRM is a convenient way 
of monitoring both the degree of damage and the effectiveness of the UDG treatment. 
These findings have immediate and important implications for cancer diagnostics 
where FFPE DNA is used as the primary genetic material for mutational studies 
guiding personalised medicine strategies and where simple effective strategies to 
detect mutations are required.
INTRODUCTION
Recent advances in molecularly targeted therapies 
have  led  to  the  increased  use  of  formalin-fixed  and 
paraffin-embedded (FFPE) tissues for the detection of 
mutational biomarkers that can predict clinical response in 
cancer patients [1, 2]. However, when DNA derived from 
FFPE tissues is used, the detection of mutations is often 
hampered both by extensive DNA degradation and by the 
presence of sequence artefacts. Oncotarget 2012; 3:  546-558 547 www.impactjournals.com/oncotarget
Whereas degradation can be compensated for by 
the use of shorter amplicons in PCR detection methods, 
the sequence artefact problem has up to now remained 
intractable. The propensity of FFPE DNA to generate 
non-reproducible  sequence  artefacts  when  it  is  used 
as template for PCR amplification is well known [3-6]. 
Sequence artefacts arising from FFPE DNA are especially 
problematic when only limited amounts of template DNA 
are used for PCR amplification [4, 7]. Importantly, the use 
of high fidelity DNA polymerases that possess a 3’→5’ 
proofreading activity do not lead to elimination of the 
sequence artefacts, indicating a template problem rather 
than  an  amplification  problem  [4,  7]. Although  DNA 
modifications due to spontaneous hydrolysis and oxidative 
damage have been suggested as possible mechanisms [8, 
9], the actual causes of sequence artefacts in FFPE DNA 
remain poorly understood. 
Previously,  we  reported  that  C:G>T:A  base 
substitutions  are  the  predominant  type  of  sequence 
artefacts in FFPE DNA [4]. Significantly, similar sequence 
artefacts are also frequently detected in ancient DNA 
when assessed by sequencing after PCR amplification 
[10-13]. In ancient DNA, deamination of cytosine bases 
is the primary cause of C:G>T:A sequence artefacts and 
treatment  with  uracil-DNA  glycosylase  (UDG)  prior 
to  PCR  amplification  markedly  reduces  the  C:G>T:A 
sequence  artefacts  [10].  Given  the  identity  of  the 
predominant mutational change we observed in FFPE 
DNA, we considered it plausible that the FFPE sequencing 
artefacts share the common underlying cause of cytosine 
deamination.
Uracil-DNA  glycosylase  is  a  DNA  repair 
enzyme that removes uracil lesions by hydrolyzing the 
N-glycosidic bond between the uracil base and the sugar 
phosphate backbone on the DNA. The resulting abasic 
sites are then repaired by the base excision DNA repair 
system. However, if cytosine deamination has occurred 
in FFPE tissues, the unrepaired uracil lesions will cause 
C>T (and thereby G>A) sequence artefacts after PCR 
amplification. 
Therefore,  the  aims  of  the  current  study  were 
firstly to examine whether C:G>T:A sequence artefacts 
predominated in amplicons from FFPE tissue derived 
DNA that appeared mutation positive upon high resolution 
melting (HRM) analysis, secondly to assess the effect of 
treating FFPE DNA with UDG on HRM and sequence 
artefacts,  and  finally  to  examine  the  effect  of  UDG 
treatment on detection of true sequence changes. The 
frequency of sequence artefacts was also assessed by a 
limited copy number - high resolution melting (LCN-
HRM) methodology, where a deliberately low template 
copy  number  is  used  for  a  stochastic  enrichment  of 
sequence artefacts. For the regions that we analyzed, we 
found that C:G>T:A sequence artefacts are predominantly 
caused by uracil lesions from FFPE DNA and treatment 
with UDG prior to PCR amplification markedly reduces 
these artefacts without affecting true mutational sequence 
changes. 
RESULTS
HRM and sequence artefacts detected in FFPE 
DNA for an AKT1 exon 4 amplicon
High  resolution  melting  (HRM)  is  a  mutation 
screening  methodology  that  is  especially  efficient  for 
scanning for DNA sequence variants due to the formation 
of heteroduplexes when sequence variants are present [14]. 
Heteroduplex-positive samples can then be sequenced to 
identify the underlying sequence variants. 
When screening DNA from FFPE samples, we have 
often observed that some PCR products showed melting 
patterns with heteroduplexes typical of the presence of 
a low level variant although no sequence variant could 
be  identified  by  Sanger  sequencing.  Investigation  of 
these products using the limited copy number - HRM 
(LCN-HRM)  methodology  showed  either  a  low-level 
mutation present below the analytical sensitivity of Sanger 
sequencing, or a cluster of non-reproducible sequence 
changes with an excess of C:G>T:A transitions, or both 
[4].
For this study, we first re-examined a HRM assay 
developed for the detection of AKT1 E17K (c.49G>A) 
mutations [15]. We had previously used this assay to 
screen 73 squamous cell lung carcinoma DNA samples 
[16].  Aberrant  melting  profiles  with  heteroduplexes, 
indicative of the presence of sequence variants, were 
detected for 15 of the screened DNA samples (Figure 1, 
Panels A and B). Two independent PCR reactions from 
each of those 15 samples (generated with an estimate of 5 
ng of input DNA) were analysed by Sanger sequencing. 
No E17K mutations were detected as previously reported 
[16]. 
However, other sequence variants were identified 
by  Sanger  sequencing  of  the  DNA  in  one  or  both 
replicates for 5 of the HRM positive tumours (Table 1). 
None of the sequence changes were detected more than 
once in the same sample or in different samples. The 
observed sequence variants comprised multiple single 
base substitutions, predominantly C:G>T:A transitions. 
Due to the random distribution of the sequence changes 
throughout the AKT1 sequence and the non-reproducibility 
of individual sequence changes in replicates, those base 
substitutions were interpreted as ‘sequence artefacts’. 
Significantly,  when  a  higher  amount  of  input 
DNA (25 ng) was used for PCR amplification, sequence 
variants were now not detected by Sanger sequencing 
in either replicate of four of these five positive FFPE 
DNA samples. The use of low amounts of template in 
the PCR reactions often allows variant-bearing templates Oncotarget 2012; 3:  546-558 548 www.impactjournals.com/oncotarget
to be present above the analytic sensitivity of Sanger 
sequencing as a consequence of stochastic enrichment. 
Thus, fewer sequence artefacts are detectable by Sanger 
sequencing with higher amounts of input templates. The 
five positive samples had a lower DNA concentration as 
judged by the time of amplification and thus had lower 
template copy numbers. Accordingly, it is likely that any 
sequence variants that were present in the remaining ten 
HRM positive samples (which had a similar block age 
distribution: 7-17 years) were not detected by Sanger 
sequencing due to the overall greater number of template 
copies present.
Uracil lesions in FFPE DNA cause HRM-detected 
sequence artefacts 
If  uracil  was  present  in  the  FFPE  DNA  as  a 
consequence of the deamination of cytosine, the observed 
C:G>T:A changes could be explained due to the base 
pairing of uracil with adenine during the first cycle of 
PCR amplification. As the sequence artefacts detected in 
the FFPE tumour DNAs were almost exclusively C:G>T:A 
base substitutions (16/17), we reasoned that the C:G>T:A 
sequence artefacts could be eliminated by treating FFPE 
DNA with uracil-DNA glycosylase (UDG). 
We thus repeated the AKT1 PCR/HRM assay after 
including a UDG treatment step to examine whether a 
reduction of C:G>T:A artefacts could be detectable in 
the melting profiles. The five FFPE DNA samples that 
had revealed AKT1 variants after Sanger sequencing 
were treated with four different concentrations of UDG 
(0.1, 0.25, 0.5, and 1 units/reaction) and were then tested 
using the same AKT1 PCR/HRM assay conditions. When 
the decrease of sequence artefacts was judged by the 
reduction of the early melting heteroduplex component 
in  HRM  analysis,  there  was  a  marked  reduction  of 
Figure 1: The melting profiles of FFPE DNA before and after UDG treatment. The melting profiles of the AKT1 HRM assay 
for three representative FFPE DNA samples (SCC8, SCC11, and SCC39) without (Panels A and B) and with UDG treatment using four 
different UDG concentrations (Panels C – F) are shown. The early melting profiles that are indicative of heteroduplex formation were seen 
in all three samples without UDG treatment. UDG treatment prior to PCR amplification resulted in a marked reduction of heteroduplex 
formation. Panel A: Normalised plot without UDG treatment. Panel B: First negative derivative plot without UDG treatment. Panels C – F: 
First negative derivative plots with a concentration of 0.1, 0.25, 0.5, and 1 UDG unit/reaction, respectively. The early melting region of the 
heteroduplexes is indicated with a blue arrow. Oncotarget 2012; 3:  546-558 549 www.impactjournals.com/oncotarget
heteroduplex formation in all of the five samples at all 
four UDG concentrations (Figure 1, Panels C-F). Of note, 
treatment with UDG did not increase the quantification 
cycle (Cq) value in any of the five samples, indicating that 
the amounts of amplifiable template were not substantially 
reduced after UDG treatment for this region (Table 2). 
We  also  tested  the  remaining  10  HRM  heteroduplex 
positives to see whether uracil-induced sequence artefacts 
were also the underlying cause of false positives in these 
DNA samples. When repeated after UDG treatment (0.5 
units/reaction), the marked reduction of the early melting 
pattern was similarly seen in all these 10 samples (results 
not shown).
Semi-quantitative assessment of AKT1 exon 4 
sequence artefacts using LCN-HRM
Low copy number (LCN)-HRM is an adaptation of 
HRM where the samples are diluted in so that only a few 
templates are used in each PCR amplification, enabling 
a stochastic enrichment of sequence variants in some 
tubes when multiple replicates are analysed [4]. Both true 
mutations and sequence artefacts can be detected on the 
basis of the formation of heteroduplexes [4].
Three  of  the  five  FFPE  DNA  samples  (SCC7, 
SCC8, and SCC14) with known high levels of sequencing 
artefacts in AKT1 exon were chosen for testing by LCN-
HRM. An estimated 100 pg of FFPE DNA was used 
and each sample was tested in 60 replicates. LCN-HRM 
reactions showing different melting patterns compared to 
that of wild-type controls were interpreted as positive for 
the presence of a sequence artefact(s). 
A high proportion of LCN-HRM positive replicates 
was seen in all three samples (Table 3 and Figure 2), 
varying from 57% (SCC7, 34 of 60) to 40% (SCC8, 
24 of 60) and 33% (SCC14, 20 of 60). After UDG pre-
treatment, there was a marked reduction in the frequency 
of LCN-HRM positives: 8% in SCC7 (7-fold reduction), 
17% in SCC8 (2.3-fold reduction), and 5% in SCC14 (6.6-
Table 1: Sequence artefacts detected in FFPE DNA samples by Sanger sequencing.
Sample Age of block 1st sequencing# 2nd sequencing##
SCC7 17 yrs
1. c.57C>T, c.101C>T
2. WT
1. WT
2. WT
SCC8 17 yrs
1. c.81C>T, c.145G>A
c.153C>T, c.162C>T
2. c.102C>T, c.110G>A
1. WT
2. WT
SCC11 16 yrs
1. c.67C>T
2. c.133G>A
1. c.99C>T, c.117G>A
2. c.105C>T, c.152C>T
SCC14 15 yrs
1. c.49G>T, c.165C>T
2. WT
1. WT
2. WT
SCC39 7 yrs
1. c.90G>A
2. WT
1. WT
2. WT
#Two independent PCR products that were generated with 5 ng of FFPE DNA were sequenced. 
##Two independent PCR products generated with 25 ng of FFPE DNA were sequenced. 
1. The result for the first replicate. 
2. The result for the second replicate. WT: wild-type.
Table 2: The quantification cycle (Cq) values determined in AKT1 exon 4 after treatment of 
FFPE DNA with four different concentrations of uracil-DNA glycosylase.
Sample
UDG concentrations (units/reaction)
0 0.1 0.25 0.5 1
SCC7 28.2 28.1 28.1 28 27.9
SCC8 28.4 28.4 28.3 28.2 28.4
SCC11 28.5 28.6 28.4 28.5 28.3
SCC14 28.4 28.1 28.2 28.2 28.2
SCC39 30.9 31.2 30.7 30.7 30.6Oncotarget 2012; 3:  546-558 550 www.impactjournals.com/oncotarget
fold reduction). These results confirm that uracil lesions 
present in FFPE DNA are the major cause of sequence 
artefacts for the genomic region investigated.
Sequencing verification of uracil lesions in FFPE 
DNA as a cause of artefacts
We then examined whether the dramatic reduction 
of heteroduplex formation after UDG treatment in these 
samples was consistent with a decline in the number of 
Figure 2: The effect of UDG treatment on sequence artefacts in AKT1 as assessed using LCN-HRM. The frequency of 
sequence artefacts in the AKT1 sequence were assessed in three FFPE DNA samples (SCC7, SCC8, and SCC14) with and without UDG 
treatment using LCN-HRM. The melting profiles of 60 individual LCN-HRM products are presented in the negative first derivative plot. 
Positive LCN-HRM reactions are shown in red and wild-type reactions are shown in green. There is a marked reduction in the number 
of LCN-HRM positive reactions after UDG treatment in all three samples. In SCC7, a total of 34 reactions were positive without UDG 
treatment (Panel A), which is markedly reduced to 5 after UDG treatment (Panel B). In SCC8, 24 and 10 LCN-HRM reactions were positive 
without (Panel C) and with UDG treatment (Panel D), and 20 and 3 LCN-HRM positives are found without (Panel E) and with UDG 
treatment (Panel F) in SCC14. 
Table 3: The LCN-HRM positive rate in AKT1 exon 4 for three FFPE DNA samples before and after 
UDG treatment.
  Without UDG treatment With UDG treatment
Sample Amp
(%)
HRM
 Pos (%)
HRM
 Neg (%)
Amp
(%)
HRM
 Pos (%)
HRM
 Neg (%)
SCC7 60 (100) 34 (57) 26 (43) 60 (100) 5 (8) 55 (92)
SCC8 60 (100) 24 (40) 36 (60) 57 (95) 10 (17) 47 (83)
SCC14 60 (100) 20 (33) 40 (67) 57 (95) 3 (5) 54 (95)
Amp: amplification, HRM: high resolution melting, Neg: negative, Pos: positive.Oncotarget 2012; 3:  546-558 551 www.impactjournals.com/oncotarget
sequencing artefacts. The five FFPE DNA samples with 
Sanger-sequencing detectable sequence artefacts in the 
AKT1 gene were treated with 0.5 units of UDG prior to 
multiple independent PCR amplifications and then were 
analysed by Sanger sequencing. 
When  these  five  FFPE  DNA  samples  had  been 
sequenced without UDG treatment, a total of 12 C:G>T:A 
sequence artefacts had been detected from 10 independent 
PCR products (12/10, mean 1.2/sequencing read). There 
was  a  very  marked  reduction  of  C:G>T:A  sequence 
artefacts when the FFPE DNA samples were sequenced 
after  UDG  treatment  (Table  4).  In  total,  only  seven 
C:G>T:A changes could be observed after sequencing of 
32 PCR products derived from UDG treated DNA (7/32, 
mean 0.2/sequencing read). 
Significantly,  all  seven  remaining  sequence 
artefacts, were detected at CpG dinucleotides, consistent 
with  deamination  of  5-methylcytosine  to  thymine  at 
methylated cytosines (Figure 3). It is likely that these 
CpG cytosines are methylated as they are part of the 
AKT1 gene body. Thymine lesions due to deamination of 
5-methylcytosine will not be repaired by UDG treatment. 
These results indicate that most, if not all, uracil-induced 
C:G>T:A sequence artefacts are removed by our standard 
conditions of 0.5 units of UDG.
Uracil lesions in FFPE DNA cause sequence 
artefacts for a BRAF exon 15 amplicon
The  same  panel  of  15  DNA  samples  that  were 
apparently AKT1 mutation positive was also tested for 
BRAF exon 15 mutations by HRM to examine whether 
uracil lesions affect other assays. All 15 samples showed 
heteroduplexes  indicating  that  sequence  variants  were 
present in the BRAF templates. After UDG treatment, the 
melting curves of those samples were superimposable on 
the wild-type controls (Figure 4, Panels A and B), again 
consistent with uracil being the primary cause of sequence 
artefacts for BRAF exon 15. 
To further examine whether the aberrant melting 
profiles of BRAF HRM results were caused by sequence 
artefacts,  five  of  the  15  HRM  positive  samples  were 
randomly selected for Sanger sequencing with and without 
UDG pre-treatment. An estimated 100 pg of FFPE DNA 
was  used  for  LCN-PCR  amplification.  Multiple  PCR 
products (9-10 for each sample) were then individually 
sequenced  (Table  4).  Sequencing  of  untreated  PCR 
products identified fifteen C:G>T:A sequence artefacts 
from  46  sequencing  replicates  (15/56,  mean  0.3/
sequencing).  Remarkably,  no  sequence  artefacts  were 
detected in 48 sequencing replicates after UDG treatment. 
These results again show that uracil lesions are a major 
source of artefacts in PCR amplicons from FFPE DNA 
and that UDG treatment can systemically remove these 
uracil lesions.
Artefact-induced false HRM positives in EGFR 
exon 19
Previously, we had also reported several non-small 
cell  lung  cancer  (NSCLC)  tumour  DNA  samples  that 
showed discordant results in the EGFR mutation status 
between HRM and Sanger sequencing [17]. Five samples 
showed heteroduplex positive melting patterns for EGFR 
exon  19  indicating  the  presence  of  sequence  variants 
although no EGFR mutations could be detected by Sanger 
sequencing. We therefore examined whether uracil lesions 
were the underlying cause of these false HRM positives in 
those samples. When the samples were tested after UDG 
Figure 3: Sequence artefacts detected in FFPE DNA 
by Sanger sequencing. Multiple non-reproducible sequence 
artefacts detected in the AKT1 sequence from FFPE DNA are 
shown. Panel A: Four sequence artefacts detected in the SCC8 
sample without UDG treatment. Three of the sequence artefacts 
(c.81C>T, c.145G>A and c.153C>T) were found in the same 
amplicon  from  one  replicate  and  the  c.110G>A  change  was 
detected in the second replicate. Panel B: Four sequence artefacts 
detected  in  three  FFPE  DNA  samples  (SCC7,  SCC11,  and 
SCC14) after UDG treatment. c.122G>A and c.143G>A changes 
were  detected  in  different  replicates  from  the  SCC7  sample. 
A  c.125C>T  (SCC11)  and  a  c.175C>T  (SCC14)  change  was 
found in a replicate of SCC11 and SCC14 respectively. All of 
the C:G>T:A changes that were found after UDG treatment were 
detected in the sequence context of CpG dinucleotides. Oncotarget 2012; 3:  546-558 552 www.impactjournals.com/oncotarget
Figure 4: UDG treatment reduces artefactual false positives by HRM. Sequence artefacts arising from uracil lesions can cause 
false HRM positives by formation of heteroduplexes. Treatment of FFPE DNA prior to PCR amplification removes uracil lesions, resulting 
in markedly reducing false HRM positives. BRAF exon 15 and EGFR exon 19 HRM results of three representative samples are shown. 
Panel A: Normalised plot for BRAF exon 15 without UDG treatment. Panel B: Normalised plot for BRAF exon 15 with UDG treatment. 
Panel C: Normalised plot for EGFR exon 19 without UDG treatment. Panel D: Normalised plot for EGFR exon 19 with UDG treatment.
Table  4: Artefacts  detected  by  Sanger  sequencing  in  FFPE  DNA  before  and  after  UDG 
treatment in the AKT1, BRAF and EGFR assays. 
Sample Gene Without UDG treatment With UDG treatment
No. of artefacts No. of seq Artefacts/
sequence
No. of artefacts No. of seq Artefacts/
sequence
SCC7 AKT1 2 2 1 2 6 0.3
SCC8 AKT1 6 2 3 2 6 0.3
SCC11 AKT1 2 2 1 1 6 0.2
SCC14 AKT1 2 2 1 1 7 0.2
SCC39 AKT1 1 2 0.5 1 7 0.2
SCC3 BRAF 4 9 0.4 0 10 0
SCC6 BRAF 2 9 0.2 0 10 0
SCC9 BRAF 4 9 0.4 0 9 0
SCC16 BRAF 4 9 0.4 0 9 0
SCC38 BRAF 1 10 0.1 0 10 0
TX34 EGFR 9 9 1 0 10 0
TX41 EGFR 7 10 0.7 0 10 0
TX185 EGFR 9 10 0.9 1 8 0.1
Total 53 85 0.6 8 108 0.07Oncotarget 2012; 3:  546-558 553 www.impactjournals.com/oncotarget
treatment, the melting profile of each individual sample 
was identical to the wild-type controls (results for three 
of these samples are shown in Figure 4, Panels C and D). 
To further examine whether sequence artefacts were 
underlying cause of the false HRM positive results, three 
of the five HRM positive NSCLC samples were randomly 
selected for further study. PCR was carried out at low 
copy number conditions using an estimated 100 pg of 
FFPE DNA. Multiple independent PCR products (8 – 10 
replicates) of each sample were Sanger sequenced without 
prior screening by HRM (Table 4). Twenty five sequence 
artefacts (all either C>T or G>A) from 16 of 29 total 
sequencing replicates were identified when FFPE DNA 
was  sequenced  without  UDG  treatment.  Significantly, 
there was a remarkable reduction of sequence artefacts 
after  UDG  pre-treatment.  Only  one  C>T  artefact 
(c.2249C>T) was detected from a total of 29 sequencing 
replicates. This result again indicates that uracil lesions in 
FFPE DNA can cause false positive results and that UDG 
treatment prior to PCR amplification reduces the false 
positive rate substantially.
No adverse effect on detection of true mutations 
by UDG treatment
We  examined  whether  treatment  of  FFPE  DNA 
with UDG affects the detection of true sequence changes 
Figure 5: Detection of true KRAS and EGFR mutations after UDG treatment. The effect of UDG treatment on detection 
of various types of true mutations are examined using a set of FFPE DNA samples harbouring either KRAS or EGFR exon 19 deletions 
and exon 20 insertion mutations. All KRAS-mutant and EGFR-mutant samples are correctly identifiable by HRM or Sanger sequencing 
regardless of UDG treatment. The positions of KRAS mutations and representative nucleotides of EGFR mutations are indicated by a 
red asterisk. Panel A: Sequence traces of KRAS exon 2 before and after UDG treatment. Both TX23 and TX63 samples harbour KRAS 
c.35G>A mutations and HCT116 cell line DNA contains a KRAS c.38G>A mutation. Panel B: Sequence traces of EGFR exon 19 before 
and after UDG treatment. Both TX35 and H1650 harbour EGFR p.E746_A750del mutations and TX48 harbours a p.T751_I759delinsN 
mutation. Panel C: Sequence traces of EGFR exon 20 before and after UDG treatment. TX202, TX383 and TX440 samples harbour EGFR 
p.C775_R776insPA, p.H773_R776insYNPY, and p.D770_H773insGSVD, respectively. Panel D: Difference plots of low-level KRAS-
mutant samples before (left) and after UDG treatment (right). KRAS mutations detected are c.35G>T (N1 9), c.35G>T (N1 46), c.35G>C 
(N1 53), c.34G>T (TX450). RPMI8226 cell line DNA contains a KRAS c.35G>C mutation.Oncotarget 2012; 3:  546-558 554 www.impactjournals.com/oncotarget
using KRAS-mutant or EGFR-mutant NSCLC samples. 
Firstly,  four  NSCLC  FFPE  DNA  samples  harbouring 
KRAS c.34G>A mutations were chosen because the G>A 
base change has been frequently detected as sequence 
artefacts in FFPE DNA. Compared to the sequencing 
results obtained without UDG treatment, the same KRAS 
mutations were clearly detectable after UDG treatment, 
indicating  that  true  G>A  sequence  changes  were  not 
affected by UDG treatment (Figure 5, Panel A). 
We  also  tested  the  effect  of  UDG  treatment  on 
detection of non-G>A changes i.e. in-frame deletions and 
insertion mutations using six NSCLC tumours harbouring 
either  EGFR  exon  19  or  20  mutations.  The  identical 
EGFR mutations were detectable by Sanger sequencing 
regardless of UDG treatment (Figure 5, Panels B and C). 
It is also important to confirm that UDG treatment 
does not affect the detection of true mutations present at 
low levels as often seen in clinical samples. We tested 
four NSCLC FFPE DNA samples harbouring low-level 
KRAS mutations present below the analytic sensitivity of 
Sanger sequencing. In these samples, KRAS mutations 
could be detected by HRM and identified by sequencing 
of LCN-HRM positive PCR products (c.34G>T in TX450, 
c.35G>T in N1 9 and 46, and c.35G>C in N1 53). All four 
samples were clearly still positive by HRM for KRAS 
mutations after UDG treatment (Figure 5, Panel D right). 
Therefore, UDG treatment does not affect the detection of 
low-level mutations. In summary, the treatment of FFPE 
DNA with UDG did not compromise the detection of true 
single base substitutions, small deletions, and insertion 
mutations in the KRAS and EGFR genes.
DISCUSSION
FFPE tissue is often the only source of DNA for 
molecular  diagnostics.  However,  non-reproducible 
sequence artefacts are more frequently observed in FFPE 
Figure 6: Uracil lesions in FFPE DNA leading to sequence artefacts and in vitro removal of uracil by uracil-DNA 
glycosylase. Spontaneous cytosine deamination is a frequent DNA damage that takes place at a rate of 70 - 200 events per day in the 
human genome. In normal cells, the resulting uracil lesions are effectively removed by UDG. The resulting abasic sites are then repaired 
by the base excision DNA repair system. However, in biopsy specimen, if cytosine deamination occurs during sample collection, formalin 
fixation, and fixed tissue storage, the resulting uracil lesions cannot be repaired due to the absence of functional DNA repair proteins. When 
DNA is extracted from the tissue with uracil lesions and then used as template for PCR amplification, transitional C:G>T:A sequence 
artefacts are generated as uracil efficiently pairs with adenine. The generation of artefactual C:G>T:A transitions from the uracil lesions 
in FFPE DNA can be effectively eliminated by treating FFPE DNA with UDG in vitro prior to PCR amplification. Abasic sites generated 
by the removal of uracil bases may reduce the extension by DNA polymerase and strand breakage during the repetitive exposure to 
high temperature during PCR cycling. Thus, treatment of FFPE DNA with UDG prior to PCR amplification eliminates the generation of 
artefactual C:G>T:A transitions arising from uracil lesions.Oncotarget 2012; 3:  546-558 555 www.impactjournals.com/oncotarget
DNA than in fresh frozen DNA after PCR amplification 
[3, 5, 18]. Sequence artefacts arising from FFPE DNA 
can be misinterpreted as true mutations unless verified 
by the sequencing of independent PCR products. This is 
especially true when low template amounts are used in the 
amplification as often is the case with FFPE DNA [4]. A 
meta-analysis of 3381 somatic EGFR mutations in 12,244 
NSCLC  patients  reported  that  71.3%  of  the  reported 
EGFR mutations were only found in a single case [19], 
strongly suggesting that many of these non-canonical 
mutations are artefactual. Therefore, the identification of 
the causes of sequence artefacts in FFPE DNA as well as 
the development of strategies for elimination of sequence 
artefacts is imperative for accurate detection of mutational 
biomarkers in clinical samples. 
Our interest in this area was a result of observing 
that FFPE DNA samples often gave HRM results that 
were difficult to interpret as exemplified by the mutation 
screening presented in the Results section. This problem 
was sample dependent as shown by the samples that were 
falsely  positive  for  both  AKT1 and BRAF mutations. 
However, certain amplicons were more prone to error 
and longer amplicons more so than shorter amplicons. In 
addition, the CG content of an amplicon is important. The 
AKT1 amplicon generated by our HRM assays contains 
a total of 24 C or G bases within the 37 bp between the 
primers, and thus comprises many potential targets for 
deamination. 
HRM analysis allows rapid screening of sequence 
artefacts  without  extra  handling  of  PCR  products. 
Individual sequence artefacts, although present at different 
nucleotide positions, cumulatively influence on the final 
melting profile through the formation of heteroduplexes. 
We thus used HRM as a convenient methodology for the 
global detection of sequence artefacts. Furthermore, to 
assess the frequency of PCR artefacts, we used LCN-HRM 
as sequence artefacts are more readily detectable when 
low copy numbers of DNA template are used for PCR 
amplification [4, 7]. This is a result of the high proportion 
of damaged DNA and the stochastic enrichment of these 
sequences  allowing  them  to  be  detectable  by  Sanger 
sequencing.
We  found  that  treatment  of  FFPE  DNA  with 
UDG prior to PCR amplification markedly reduced the 
generation of sequence artefacts in damaged FFPE DNA. 
Although we did not directly examine the presence of 
uracil lesions in FFPE DNA, the drastic reduction of 
sequence artefacts after UDG treatment in several sets 
of FFPE DNA samples indicates that uracil lesions are 
commonly present. 
The most common sequence artefacts identified in 
FFPE DNA were C:G>T:A changes, which is consistent 
with our previous study using LCN-HRM and sequencing 
[4]. As these sequence artefacts were dramatically reduced 
by  UDG  treatment,  this  indicates  that  uracil  lesions, 
are responsible for the transitional C:G>T:A sequence 
artefacts.
Two groups have previously examined the effect 
of UDG treatment on reduction of sequence artefacts in 
FFPE DNA [20, 21]. Marchetti et al. reported (in passing) 
that  artefactual  C:G>T:A  substitutions  in  the  EGFR 
gene were not detectable if FFPE DNA template was 
treated with UDG prior to PCR amplification, However, 
the data was not shown, nor did this alter practice in 
molecular  diagnostics,  not  even  by  the  same  group 
[20]. Subsequently, Lamy et al. reported that cytosine 
deamination was not the major mechanism for generation 
of sequence artefacts in colorectal cancer FFPE DNA as 
UDG treatment failed to eliminate G>A sequence artefacts 
in 15 of the 16 colorectal samples tested [21]. 
In our experiments with AKT1 exon 4, the UDG 
concentration  of  0.1  units/reaction  was  sufficient  for 
effective  removal  of  uracil  bases  as  judged  by  the 
formation of heteroduplexes in high resolution melting 
assays. Highly damaged FFPE DNA samples or more 
different amplicons may require higher amounts of UDG 
enzyme for successful treatment. We use 0.5 units/reaction 
to give us a wide margin of error. We consider it likely that 
the failure of UDG treatment in reducing G>A sequence 
artefacts by Lamy et al. was the use of a sub-optimal 
amount of UDG to treat a high amount (500 ng) of FFPE 
DNA. 
There are two possible explanations for our observed 
reduction of sequence artefacts in FFPE DNA by UDG 
treatment (Figure 6). Abasic sites generated by excision 
of uracil bases in FFPE DNA can block the extension 
by DNA polymerase [22-24]. Also, a DNA strand with 
abasic sites is more susceptible to strand breakage during 
the repetitive exposure to high temperature during PCR 
cycling. A high proportion of DNA templates that contain 
abasic sites, as high as 90%, can undergo strand breakage 
in the first step of PCR amplification [24]. 
Importantly,  true  sequence  changes  present  in 
tumour  samples  are  not  affected  by  UDG  treatment, 
regardless of the type of sequence changes. FFPE DNA 
samples with either KRAS  (single  base  substitutions 
including  G>A  changes)  or  EGFR  mutations  (short 
deletions/insertions)  remained  identifiable  after  UDG 
treatment. Moreover, the elimination of uracil-induced 
sequence artefacts helps to avoid false positive results 
for mutation detection by HRM analysis. If in addition, 
uracil is incorporated into the PCR product via UTP-
containing  primers  or  the  use  of  dUTP  during  PCR 
amplification, UDG pre-treatment can also be used to 
prevent another source of false positives i.e. carryover of 
PCR amplification (25).
Although C:G>T:A transitions are the most frequent 
type of sequence artefacts, A>G transitions and G>T and 
G>C  transversions  have  also  been  identified  in  FFPE 
DNA [4, 21, 26]. We found that 5 to 17% of LCN-HRM 
reactions remained positive even after UDG treatment, 
suggesting that uncharacterised DNA damages, other Oncotarget 2012; 3:  546-558 556 www.impactjournals.com/oncotarget
than uracil lesions, are also present in FFPE DNA. One 
possibility  explaining  the  remaining  mutations  after 
UDG treatment of FFPE samples is the presence of true 
low frequency mutations. Another plausible explanation 
is deamination of 5-methylcytosine, which is supported 
by our data showing that all sequence variants detected 
after UDG treatment are C>T substitution occurred in 
the sequence context of CpG dinucleotides. Currently, 
additional studies are thus being undertaken to test these 
idea and also to further delineate DNA damage that 
induces sequence artefacts in FFPE DNA.
In conclusion, we identified that the deamination 
of cytosine to uracil is responsible for most artefactual 
C:G>T:A transitions arising from FFPE DNA. Removal 
of uracil lesions by UDG treatment markedly reduced 
C:G>T:A sequence artefacts with no detrimental effect on 
detection of true mutations. 
The incorporation of a simple UDG treatment step 
will thus help to reduce false positives in FFPE DNA 
samples. This will considerably facilitate accurate clinical 
analysis. This additional step is simple to incorporate into 
existing assays. We were able to incorporate the UDG into 
the PCR reaction mix allowing the UDG pretreatment step 
to occur in a seamless fashion with the PCR and the HRM. 
The applications of this technique also immediately 
extend  to  the  developing  use  of  second  generation 
sequencing methodologies for the analysis of clinical 
FFPE samples. In particular, an important application will 
be to the study of intra-tumoral heterogeneity where it is 
critical to minimize every non-specific sequence change to 
understand the true extent of variation.
MATERIALS AND METHODS
Samples and DNA extraction
Formalin-fixed paraffin-embedded non-small cell 
lung cancer (NSCLC) tissues were obtained from the 
Austin  Hospital  (Melbourne, Australia)  and  the  Peter 
MacCallum Cancer Centre (Melbourne, Australia). For 
DNA  extraction,  tumour-enriched  regions  identified 
by  a  pathologist  at  Peter  MacCallum  Cancer  Centre 
were  microdissected  from  5  µm  tissue  sections.  The 
microdissected tissues were mixed with the ATL buffer 
(Qiagen,  Hilden,  Germany),  were  heat-treated  for 
15  minutes  at  98ºC  ,  and  then  underwent  proteinase 
K  digestion  for  3  days  at  56ºC.  Genomic  DNA  was   
extracted using the DNeasy Tissue and Blood kit (Qiagen) 
according  to  the  manufacturer’s  protocol.  Extracted 
DNA  was  quantified  using  a  NanoDrop  ND-1000 
Fluorospectrometer (NanoDrop, Wilmington, DE). This 
study was approved by the Ethics of Human Research 
Committee at the Peter MacCallum Cancer Centre with 
the approval number of 03/90.
Sequence variant detection using high resolution 
melting
Sequence variants in the AKT1  exon  4,  KRAS 
exon  2,  and  EGFR  exon  19  and  20,  were  scanned 
by  HRM  using  the  conditions  previously  described 
[15,  17,  27].  The  region  surrounding  codon  600 
in  BRAF  exon  15  was  also  screened  by  HRM 
using  primers  tagged  with  m13  sequences  (m13 
sequences  in  lower  case);  forward  5’-caggaaacag 
ctatgaccCATGAAGACCTCACAGTAAAAATAGGT-3’ 
and  reverse  5’-tgtaaaacgacgg 
cagtCATCCACAAAATGGATCCAGACAAC-3’.  PCR 
cycling and HRM was performed on the RotorGene Q 
instrument (Qiagen). The reaction mixture was prepared 
in a final volume of 20 μL as follows; 1 x PCR buffer, 
2.5 mM MgCl2, 400 nM of each primer, 5 ng of FFPE 
DNA, 200 µM of dNTPs, 5 µM of SYTO 9 (Invitrogen), 
and 0.5 U of HotStar Taq polymerase (Qiagen). The PCR 
cycling and melting conditions were as follows; an initial 
incubation at 95ºC for 15 mins, followed by 55 cycles of 
95ºC for 10 s, 60ºC for 20 s, and 72ºC for 30 s; one cycle 
of 97ºC for 1 min and a melt from 70ºC to 95ºC rising 
0.2ºC per step.
Treatment of FFPE DNA with uracil-DNA-
glycosylase (UDG)
To perform the UDG treatment and subsequent PCR/
HRM assays without opening of reaction tubes, UDG (0.5 
units/reaction, unless specified) and the UDG buffer (New 
England BioLabs, Ipswich, MA) were directly added to 
PCR/HRM master mixes. The reaction tubes were first 
incubated at 37ºC for 30 minutes for UDG treatment, 
followed by the standard PCR/HRM assay conditions on 
the RotorGene Q instrument.
Quantification of amplifiable template after UDG 
treatment
The amount of amplifiable template was measured 
in five squamous cell carcinomas of lung before and after 
UDG treatment by comparing the quantification cycle 
(Cq) values obtained from the AKT1 exon 4 HRM results. 
The  comparative  quantitation  analysis  method  of  the 
Rotor-Gene 6000 Software (v1.7) was used to determine 
the Cq values. 
Limited copy number (LCN)-HRM
In LCN-HRM, low copies of templates are used for 
PCR amplification in multiple LCN-HRM reactions to 
enable a stochastic increase in the proportion of sequence 
variant  to  wild-type  template  in  some  of  the  tubes. Oncotarget 2012; 3:  546-558 557 www.impactjournals.com/oncotarget
After PCR amplification, tubes with enriched sequence 
variants can then be determined by melting curve analysis 
[4]. LCN-HRM was used to estimate the frequency of 
sequence artefacts in FFPE DNA samples. FFPE DNA 
was first diluted with PCR grade H2O so that an estimated 
100 pg of DNA was then added to individual LCN-HRM 
reactions. All samples were tested in 60 replicates.
DNA sequencing
The  entire  coding  sequences  of AKT1  exon  4 
and EGFR exon 19 and 20, were sequenced using the 
conditions previously described [15, 17]. A part of KRAS 
exon 2 that includes codon 12 and 13 was amplified using 
the KRAS exon 2 HRM primers that were tagged with m13 
sequences. BRAF exon 15 HRM products were directly 
used as templates for sequencing reaction. Sequencing 
reaction was performed using the Big Dye Terminator 
v3.1 chemistry according to the manufacturer’s protocol 
(Applied Biosystems, Foster City, CA) using 6 μL of the 
PCR products that were purified with 2 μL of ExoSapIT 
(GE  Healthcare,  Little  Chalfont,  England).  After 
precipitation with ethanol, the sequencing products were 
ran on a 3700 Genetic Analyser (Applied Biosystems). 
The sequencing data was then analysed using Sequencher 
4.6 (Gene Codes Corporation, Ann Arbor, MI).
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